← FDA DRUG APPROVALS

FDA BLA · BLA761033

CINQAIR

reslizumab

Sponsor: TEVA RESPIRATORY LLC

APPLICATION
BLA761033
TYPE
BLA
ORIGINAL APPROVAL
2016-03-23
LATEST ACTION
2019-01-09
ROUTE
INTRAVENOUS, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

CINQAIRPrescription
RESLIZUMAB 100MG/10ML · INJECTABLE · INJECTION

Approval history

2019-01-09Labeling · Supplement 10 · standard — Label ↗AP
2016-03-23Type 1 - New Molecular Entity · Original · standard — Summary Review ↗AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Biologics industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →